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Abstract
Introduction: This work aimed at comparing the production of inflammatory and pro- and anti-angiogenic factors
by normal/reactive (N/R) or inflammatory (I) areas of the osteoarthritic synovial membrane. The effects of
interleukin (IL)-1b and chondroitin sulfate (CS) on the expression of pro- and anti-angiogenic factors by synovial
fibroblasts cells (SFC) were also studied.
Methods: Biopsies from N/R or from I areas of osteoarthritic synovial membrane were collected at the time of
surgery. The inflammatory status of the synovial membrane was characterized by the surgeon according to
macroscopic criteria, including the synovial vascularization, the villi formation and the hypertrophic aspect of the
tissue. We assessed the expression of CD45, von Willebrand factor and vascular endothelial growth factor (VEGF)
antigen by immunohistochemistry in both N/R and I biopsies. The production of IL-6, -8, VEGF and
thrombospondin (TSP)-1 by N/R or I synovial cells was quantified by ELISA. SFC were cultured in the absence or in
the presence of IL-1b (1 ng/ml) and with or without CS (10, 50, 200 μg/ml). Gene expression of pro-angiogenic
factors (VEGF, basic fibroblast growth factor (bFGF), nerve growth factor (NGF), matrix metalloproteinase (MMP)-2
and angiopoietin (ang)-1) and anti-angiogenic factors (vascular endothelial growth inhibitor (VEGI), TSP-1 and -2)
were determined by real time RT-PCR. Production of VEGI and TSP-1 was also estimated by ELISA.
Results: Immunohistochemistry showed the increase of lymphocyte infiltration, vascular density and VEGF
expression in I compared to N/R synovial biopsies. Synovial cells from I areas produced more IL-6, IL-8 and VEGF
but less TSP-1 than cells isolated from N/R synovial biopsies. The expression of pro-angiogenic factors by SFC was
stimulated by IL-1b. A time dependent regulation of the expression of anti-angiogenic factor genes was observed.
IL-1b stimulated the expression of anti-angiogenic factor genes but inhibited it after 24 h. CS reversed the
inhibitory effect of IL-1b on anti-angiogenic factors, VEGI and TSP-1.
Conclusions: We demonstrated that synovial biopsies from I areas expressed a pro-angiogenic phenotype. IL-1b
induced an imbalance between pro- and anti-angiogenic factors in SFC and CS tended to normalize this IL-1b-
induced imbalance, providing a new possible mechanism of action of this drug.
Introduction
Osteoarthritis (OA) is an important cause of pain and
disability in the ageing population. The main features of
OA include articular cartilage degradation, subchondral
bone abnormal remodeling and synovial membrane
inflammation leading to joint swelling, synovitis and
pain [1]. Angiogenesis and inflammation of synovial
membrane are closely integrated processes in OA patho-
genesis [2,3] but it remains largely unclear how inflam-
mation and angiogenesis are cross-regulated.
We hypothesized that the angiogenesis of the synovial
membrane results of an imbalance between pro-angio-
genic and anti-angiogenic factors and that interleukin (IL)-
1b, one of the most potent cytokine in OA
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physiopathology, may induce this imbalance. More pre-
cisely, we have investigated the expression of pro-angio-
genic (Vascular Endothelial Growth Factor (VEGF), basic
Fibroblast Growth Factor (bFGF), Nerve Growth Factor
(NGF), Angiopoietin (Ang)-1 and Matrix Metalloprotei-
nase (MMP)-2) and anti-angiogenic factors (Vascular
Endothelial Growth Inhibitor (VEGI), Thrombospondine
(TSP)-1 and -2) by synovial fibroblast cells (SFC) treated
by IL-1b. VEGF and bFGF are potent and extensively stu-
died pro-angiogenic factors [4]. They induce proliferation,
sprouting and tube formation of endothelial cells. NGF,
acting in concert with VEGF, also plays a role as a pro-
angiogenic factor [5]. Ang-1 is a critical mediator of the
late stages of vessel development. It maintains and stabi-
lizes mature vessels by binding to an endothelium-specific
receptor, Tie2 [6]. By promoting the breakdown of the
endothelial basement membrane, MMP-2 allows the
migration of endothelial cells and the formation of primi-
tive vessels into avascular regions of tissue [7]. TSP-1 and
-2 are among the first anti-angiogenic factors identified.
They act by blocking endothelial cell proliferation, migra-
tion and apoptosis, by reducing the availability of angio-
genic factors and by regulating the extracellular proteases
[8]. VEGI, also known as tumor necrosis factor superfam-
ily member 15 (TNFSF15) or TNF ligand related molecule
1 (TL1), is a cytokine with potent anti-angiogenic proper-
ties principally studied in cancer as an inhibitor of
endothelial cell proliferation and tumor growth [9].
VEGF [10], bFGF [11], NGF [12], Ang-1 [13] and MMP-
2 [14] are overexpressed in the synovial membrane of RA
patients compared with either normal or OA patients.
Anti-angiogenic factors, TSP-1 [15], TSP-2 [16] and VEGI
[17], are also up-regulated in RA synovial membrane.
Chondroitin sulfate (CS) is a major component of the
extracellular matrix of cartilage implicated in its elasti-
city and its resistance to loading. CS is one of the most
used molecules in the management of OA and numer-
ous clinical trials and meta-analyses have shown its clin-
ical benefits to decrease pain, improve functional
disability and reduce non-steroidal anti-inflammatory
drugs (NSAIDs) or acetaminophen consumption [18-22]
Although several mechanisms of action have been
described for this drug [23,24], the exact mechanism(s)
of action of this molecule still remains an exciting field
of investigation [25]. Taking into account the reduction
in swelling and joint effusion produced by CS on synovi-
tis of knee OA patients described in the GAIT study
[26], the evaluation of the possible effect of CS in the
angiogenic processes observed in OA synovial mem-
brane should lead at least to a better knowledge of its
mechanisms of action and may represent a major
advance in the demonstration of its efficacy.
To provide insight into the network between inflam-
mation and angiogenesis, we have compared
inflammatory (immunohistochemical staining for lym-
phocytes) and angiogenic (immunohistochemical stain-
ing for VEGF and for von Willebrand factor) status of
OA synovial membrane biopsies from normal or reac-
tive (N/R) or inflammatory (I) areas of OA knee. We
have investigated the relationship between inflammatory
markers (IL-6 and IL-8) and angiogenic markers (VEGF
and TSP-1) in synovial cells isolated from these distinct
areas of synovial membrane. We have further studied
the effects of IL-1b on the expression of pro- and anti-
angiogenic factors by SFC. The modulation of these fac-
tors by CS was also investigated.
Understanding the regulatory molecular mechanisms
of angiogenesis in OA synovial membrane should lead
to novel OA therapies which would selectively inhibit
the undesirable angiogenesis. The demonstration of
anti-angiogenic action of CS could provide a novel ther-
apeutic approach for OA targeting.
Materials and methods
Patients
Synovial tissue samples were obtained from 16 patients
(10 women, 6 men; mean age 67 years, range 54 to 89
years) with OA of the knee at the time of total knee
joint replacement surgery. All the subjects provided
their informed consent and the ethic approval (Ethic
committee agreement of Catholic University of Louvain,
n°: B403201111664) was granted for this study. For each
patient, biopsies were selected according to the macro-
scopic aspect of the synovial membrane [27,28]:
1. Normal synovial membrane (grade 0):
✓ Few translucent, slender villi with a fine vascular
network can be clearly seen
✓ Proliferation of opaque villi
2. Reactive synovial membrane (grade 0.5):
✓ Villi have normal morphology or somewhat
thicker and squat appearance
✓ Vascular network not seen due to loss
translucence
3. Inflammatory synovial membrane (grade 1):
✓ Hypervascularization of synovial membrane and/
or proliferation of hypertrophic and hyperemic villi
are apparent
Histology and immunohistochemistry of synovial
membrane
Synovial biopsies were fixed, dehydrated in xylene and
embedded in paraffin under standard procedures. Five
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μm sections were cut and deparaffinized and stained
with haematoxylin and eosin (HE) according to standard
protocol. Lymphocytes were identified by immunohisto-
chemitry using anti-CD45 antibody (dilution 1/100; M
0701, Dako, Heverlee, Belgium). Blood vessels were
visualized using anti-von Willebrand factor antibody
(dilution 1/200; A 0082, Dako, Heverlee, Belgium). Sec-
tions were also stained with anti-VEGF (dilution 1/50;
sc-152, Santa Cruz Biotechnology, Heidelberg, Germany)
antibody. Secondary antibodies, horseradish peroxidase
enzyme conjugated and 3,3’-diaminobenzidine (DAB)
substrate, were used to develop immunostaining accord-
ing to manufacturer’s instructions. Slides were counter-
stained with HE.
Isolation and culture of synovial cells
N/R and I synovium biopsies were separately digested
with collagenase from Clostridium histolyticum, Type
IA (1 mg/ml) (Sigma-Aldrich, Bornem, Belgium) in
complete medium (CM) (DMEM (Dulbecco’s Modified
Eagle’s Medium) supplemented with 10 mM HEPES,
100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM
glutamine and 10% fetal calf serum (Lonza, Verviers,
Belgium)) for four hours at 37°C. The cell suspensions
were passed through a 70-μm filter to remove any
undigested tissue. The filtered cell suspensions were
then collected by centrifugation at 800 g. Synovial cells
(SC) from either N/R or I biopsies (N/R SC or I SC)
were cultured in a 12-well plate at 2 × 105 cells per
well in 1 ml of CM, at 37°C in a 5% CO2 humidified
atmosphere. After two days, medium was changed to
eliminate non adherent cells and cultivated in fresh
medium for five days. Synovial fibroblast cells (SFC)
were obtained and used after four passages of SC in
culture flasks.
Treatment of synovial fibroblast cells
IL-1b and CS were tested on SFC. Cells were seeded
into a six-well plate at a density of 1 × 105 cells/well in
2 ml of CM. When the cells reached confluence, the
CM was replaced with 1% serum media for 24 h to ren-
der the cells quiescent. Cells were incubated in the same
medium with or without CS (10, 50, 200 μg/ml). CS (CS
Bio-Active®, Bioibérica, Barcelona, Spain) used in this
study was from bovine origin with a disaccharide sulfa-
tion profile of 63% of 4-sulfated, 31% of 6-sulfated and
6% of O-sulfated. When IL-1b (1 ng/ml) (Roche Diag-
nostics, Vilvoorde, Belgium) was used, cells were pre-
incubated with CS for 1 h before the addition of IL-1b.
DNA assay
Cells were homogenized in 0.5 ml of phosphate buffered
saline (PBS) (Lonza, Verviers, Belgium) by ultrasonic
dissociation for 15 s at 4°C. DNA content was measured
in the cell extracts using a fluorimetric method of
Labarca and Paigen [29].
Immunoassays for IL-6, IL-8, VEGF, TSP-1 and VEGI
IL-6, IL-8, VEGF, TSP-1 and VEGI were determined in
the culture supernatant by ELISA (Biosource Europe,
Merelbeke, Belgium for IL-6 and IL-8; RD System,
Abingdon, UK for VEGF and TSP-1; PeproTech, Lon-
don, UK for VEGI) using specific monoclonal and poly-
clonal antibodies according to the manufacturers’
protocols. The production of the different molecules
was expressed per μg of DNA. The results were pre-
sented as the percent of production from N/R areas.
RNA extraction and Real Time Reverse Transcriptase-
Polymerase Chain Reaction (RT PCR)
Total RNA were extracted using the RNeasy Mini Kit
(Qiagen, Venlo, Netherlands) and were reverse tran-
scribed with SuperScript III Reverse Transcriptase (Invi-
trogen, Merelbeke, Belgium) according to the
manufacturer’s instructions. The cDNAs were quantified
by real-time quantitative PCR using the LightCycler 480
instrument (Roche Diagnostics, Vilvoorde, Belgium) and
the SYBR Premix Ex Taq kit (Takara, Verviers, Bel-
gium). The level of gene expression was determined by
interpolation with a standard curve. To standardize
mRNA levels, GAPDH, a house keeping gene, was
amplified as an internal control. Gene expression was
normalized by calculating the ratio between the number
of cDNA copies of the desired gene and that of
GAPDH. The oligonucleotide primers sequences were
as follows: GAPDH forward, 5’-TTGGTATCGTG-
GAAGGACTCA-3’; GAPDH reverse, 5’-TGTCATCA-
TATTTGGCAGGTTT-3’; VEGF forward, 5’-
TGCCTTGC TGCTCTAC-3’; VEGF reverse, 5’-CACA-
CAGGATGGCTTGAA-3’; bFGF forward, 5’-TCAAAG-
GAGTGTGTGCTAACC-3’; bFGF reverse, 5’-
TTTCAGTGCCACATACCAAC-3’; NGF forward, 5’-






3’; TSP-1 forward, 5’-CAGACCGCATTGGAGATAC-3’;
TSP-1 reverse, 5’-CCATCGTTGTCATCA TCGTG-3’;
TSP-2 forward, 5’-AATGACGGTGTGACCGA-3’; TSP-
2 reverse, 5’- ACCCTCTCCATTGTTGTCT-3’; VEGI
forward, 5’-CCCTTCCTTGCAGGACT-3’; VEGI
reverse, 5’- CCCTTGGCTTATCTCCGT-3’. The results
are represented as the percentage of gene expression in
the basal condition or as the percentage of expression
obtained in the absence of CS (control) depending on
experimental procedures.
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Statistical analysis
Non-parametric Mann-Whitney U test was used to ana-
lyze statistical differences. Differences were considered
statistically significant with P-value < 0.05. Correlation
was performed by Spearman non-parametric analysis.
Results
Histological evaluation of inflammation and angiogenesis
of N/R and I synovial biopsies
A marked increase in cellularity was observed in the
intima lining of I biopsies (Figure 1) compared with N/
R biopsies. The intima lining layer of I synovial biopsies
was hyperplasic with multiple layers of cells while N/R
synovial lining was formed by one or two cell layers.
Invasive lymphoid nodes in the sublining region were
present in I biopsies, but not in N/R biopsies. I biopsies
were also characterized by villi formation. This histolo-
gical analysis validated the sampling method of biopsies
and the discrimination of N/R and I area of the synovial
membrane. We have further compared CD45, von Will-
ebrand and VEGF expression in N/R and I biopsies by
immunohistochemistry. Lymphocytes were visualized
using antibody against CD45, a transmembrane glyco-
protein expressed by leukocytes (Figure 2). In I synovial
biopsies, there was an increase in the CD45-positive
cells with a predominant localization in the intima lin-
ing. To investigate the blood vessel formation in syno-
vial membrane, we performed immunohistochemical
staining using antibody against von Willebrand factor
(Figure 3). Blood vessels were distributed throughout
the depth of the synovial membrane without preferential
distribution in the lining cells. Vascular density and ves-
sel size were higher in I than in N/R biopsies. A staining
for VEGF was observed in perivascular and sublining
cells in both N/R and in I biopsies (Figure 4). An acute
positive staining was observed in the intima lining layer
of I but not N/R biopsies.
Inflammatory and angiogenic factors expression by SC
from N/R and I areas
The production of inflammatory and angiogenic factors
by SC isolated from either N/R or I areas of the synovial
membrane was compared. N/R SC produced 8,497 ±
3,598 pg/μg DNA of IL-6, and 17,726 ± 6,682 pg/μg
DNA of IL-8.
IL-6 and IL-8 (Figure 5A, B) production by I SC was
significantly higher than those of N/R SC (for IL-6: 411
± 110% of N/R SC production, P < 0.001; for IL-8: 716
± 310% of N/R SC production, P < 0.001). I SC pro-
duced more VEGF (134 ± 16% of N/R SC production, P
< 0.001, Figure 5C) and less TSP-1 (66 ± 14% of N/R
SC production, P < 0.001, Figure 5D) than N/R SC.
In addition, we assessed the correlation between
inflammatory cytokines (IL-6, IL-8) and angiogenic fac-
tors (VEGF, TSP-1). VEGF production showed a strong
positive correlation with IL-6 and IL-8 (r = 0.67, P <
0.0001 and r = 0.65, P < 0.0001, respectively). A signifi-
cant negative correlation was obtained between TSP-1
and IL-8 (r = -0.4, P = 0.002). The correlation between
TSP-1 and IL-6 was at the limit of the statistical signifi-
cance (r = -0.25, P = 0.06).
Effect of IL-1b on mRNA expression of pro-/anti-
angiogenic factors by SFC
SFC were incubated in the absence (basal condition) or
in the presence of IL-1b (1 ng/ml) during 5 or 24 h.
The gene expression of five pro-angiogenic factors
(VEGF, bFGF, NGF, Ang1 and MMP-2) (Figure 6A) and
Figure 1 Histological analysis of NR (A) and I (B) biopsies of synovial membrane. At the time of surgery, synovial biopsies coming from NR
or I area of synovial membrane were macroscopically selected as described in Materials and methods. Biopsies were fixed, embedded in paraffin
and sectioned before staining with HE. ® intima linning, ⇒ lymphoid node.
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three anti-angiogenic factors (VEGI, TSP-1 and TSP-2)
(Figure 6B) was analyzed by real time RT PCR.
After 5 h of incubation, the expression of VEGF, bFGF
and NGF genes was increased by IL-1b (VEGF: 250 ± 58
of basal expression, P < 0.001; bFGF: 1,032 ± 99% of
basal expression, P < 0.001; NGF: 672 ± 161% of basal
expression, P < 0.001). After 24 h, the stimulating effect
of IL-1b on VEGF and bFGF genes was less marked
(respectively 173 ± 30% of basal expression, P < 0.001
and 175 ± 34% of basal expression, P < 0.001). No sig-
nificant effect of IL-1b was obtained for NGF gene
expression after 24 h of treatment. Ang-1 gene expres-
sion was not modified by IL-1b after 5 h of treatment
while a weak but significant increase was observed after
24 h (159 ± 37% of basal expression, P < 0.001). IL-1b
did not influence the MMP-2 gene expression.
Figure 6B showed the effect of IL-1b on mRNA
expression of anti-angiogenic factors. For TSP-1 and
VEGI, a biphasic time-dependent effect of IL-1b was
observed: a stimulation after 5 h of treatment (TSP-1:
140 ± 28% of basal expression, P < 0.01; VEGI: 262 ±
47% of basal expression, P < 0.001) and an inhibition
after 24 h of treatment (TSP-1: 29 ± 8% of basal expres-
sion, P < 0.001; VEGI: 41 ± 10% of basal expression, P <
0.001). A time-dependent biphasic effect of IL-1b was
also recorded on the production of TSP-1 and VEGI
proteins. After 5 h of treatment, IL-1b stimulated TSP-1
(130.2 ± 6.65% of basal expression, P < 0.01) and VEGI
(140.2 ± 10.1% of basal expression, P < 0.001) while it
inhibited TSP-1 and VEGI production after 24 h (TSP-
1: 71.3 ± 5.2% of basal expression, P < 0.01; VEGI: 77.5
± 4.23% of basal expression, P < 0.001). After 5 h of
treatment, IL-1b did not modify TSP-2 gene expression
while an inhibition was observed after 24 h (62 ± 8% of
basal expression, P < 0.001, Figure 6B).
CS modulation of pro-/anti-angiogenic factor expression
in SFC
Using real time RT-PCR technology, we investigated the
effects of CS on pro- and anti-angiogenic factors. SFC
were incubated for 5 and 24 h with increasing concen-
trations of CS (10, 50, 200 μg/ml) and with or without
IL-1b (1 ng/ml). In all tested conditions, CS did not
modify the basal expression of pro- (VEGF, bFGF, NGF,
Ang-1 and MMP-2) and anti-angiogenic (VEGI, TSP-1
and 2) genes (data not shown). The stimulating effect of
IL-1b on the expression of pro-angiogenic genes was
unaffected by CS (data not shown).
After 5 h of treatment, CS did not induce significant
changes in the IL-1b-dependent up-regulation of gene
expression of anti-angiogenic factors (data not shown).
Figure 7 showed the effect of CS on the inhibitory effect
Figure 2 Immunohistochemical detection of lymphocytes in N/R (A and C) and in I (B and D) synovial biopsies. At the time of surgery,
synovial biopsies coming from N/R or I areas were macroscopically selected as described in Materials and methods. Immunohistochemical
staining of lymphocytes was performed using anti CD45 antibody. Positive staining was detected as brown peroxidase reaction product. (A) and
(B) Global image of the section ® intima linning, ⇒ lymphoid node (C) and (D) magnification (×100) of intima lining.
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of IL-1b on the expression of VEGI, TSP-1 and TSP-2
genes observed after 24 h of treatment. After 24 h,
VEGI mRNA levels were enhanced in the presence of
200 μg/ml of CS (177 ± 26% of control, P < 0.001).
TSP-1 gene expression was significantly increased by 50
μg/ml of CS (191 ± 41.2% of control, P < 0.001) and by
200 μg/ml of CS (259.5 ± 61% of control, P < 0.001) of
CS. No significant variation of TSP-2 was obtained. At
the concentration of 50 and 200 μg/ml, CS partially
reversed the inhibitory effect of IL-1b on VEGI protein
production (Figure 8). Indeed, a significant increase of
VEGI production was observed with 50 μg/ml of CS
(115 ± 5% of control, P < 0.001). This increase was sig-
nificantly marked at 200 μg/ml of CS (156 ± 17% of
control, P < 0.001). Similarly, CS reversed the inhibitory
effect of IL-1b on TSP-1 production. CS increased TSP-
1 production in a dose dependent manner (r = 0.82, P <
0.001).
Discussion
Synovial inflammation is directly implicated in the
initiation and progression of OA [1]. Uncontrolled
angiogenesis is a critical event of synovial inflammation
and these two interdependent processes, that is, angio-
genesis and inflammation, are now considered as impor-
tant contributors of OA [2,30].
The mechanism leading to the crosstalk between
angiogenesis and inflammation is still insufficiently
clear. To contribute to the better understanding of this
crosstalk in OA synovial membrane, we have developed
an original methodology comparing inflammation and
angiogenesis in synovial membrane with different grades
of synovitis. We used the Ayral’s synovitis scores [27] to
select, in the same OA synovial membrane, biopsies
coming from N/R or I synovial areas. This method of
biopsy sampling was validated by the histological and
immunohistochemical analyses. Our results supported
Figure 3 Immunohistochemical detection of blood vessels in NR (A and C) and in I (B and D) synovial biopsies. At the time of surgery,
synovial biopsies coming from NR or I areas were macroscopically selected by as described in Materials and methods. Immunohistochemical
staining of blood vessels (®) was performed using anti-von Willebrand factor antibody. Positive staining was detected as brown peroxidase
reaction product. (A) and (B) global image of the section, (C) and (D) magnification (×100) of vessel lumens.
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those of Haywood et al. [2], who showed that the
endothelial cells density and VEGF immunoreactivity of
OA synovial membrane increased with inflammation
grade and macrophage infiltration. This study contribu-
ted to showing the concerted evolution of inflammation
and angiogenesis in OA synovial membrane.
We have shown a difference of production of pro-
inflammatory cytokines (IL-6 and IL-8), pro-angiogenic
factor (VEGF) and anti-angiogenic factor (TSP-1)
between N/R and I primary SC. These results suggested
a shift in the balance of angiogenic factors in favor of
the development of neovascularization. IL-6 and IL-8
are the most abundant cytokines found in the synovial
fluid of patients with OA and they are considered to
play a central role in synovial inflammation [28]. In OA
patients, IL-6 production in synovial fluid is correlated
with plasma C-reactive protein and with synovial inflam-
matory cells infiltration [31]. VEGF is considered as a
dominant pro-angiogenic factor which acts early in
angiogenesis inducing an increase in blood vessel per-
meability and proliferation and migration of endothelial
cells. VEGF has been associated with synovial angiogen-
esis [2]. The inhibitory effect of TSP-1 on angiogenesis
is largely described [8]. As an inhibitor of angiogenesis,
TSP-1 overexpression decreases inflammation and blood
vessel density in synovial membrane. It also reduces car-
tilage lesions in rats where OA is induced by anterior
cruciate ligament transection [32]. In addition, VEGF
production showed a strong positive correlation with IL-
6 and IL-8, while significant negative correlation was
obtained between TSP-1 and IL-8. These results high-
light the role played by VEGF and TSP-1 in the link
between inflammation and angiogenesis of the synovial
membrane.
Synovial inflammation is an important source of pro-
inflammatory mediators. IL-1b produced by synovial
cells induces a degradative cascade leading to joint
damage. In this work, we have studied the modulation
of gene expression of pro-angiogenic (VEGF, bFGF,
NGF, Ang-1, MMP-2) and anti-angiogenic (VEGI, TSP-
1 and 2) factors by IL-1b in SFC. IL-1b increased the
level of mRNA on pro-angiogenic factors. VEGF, bFGF
Figure 4 Immunohistochemical detection of VEGF in NR (A, and C) and in I (B and D) synovial biopsies. At the time of surgery, synovial
biopsies coming from NR or I areas were macroscopically selected as described in Materials and methods. NR and I synovial biopsies were
stained with anti-VEGF antibody. Positive staining was detected as brown peroxidase reaction product. (A) and (B) global image of the section,
(C) and (D) magnification (×10) of intima lining and vessel lumen.
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Figure 5 IL-6 (A), IL-8 (B), VEGF (C) and TSP-1 (D) production by primary N/R and I SC. SC were isolated from N/R and I synovial biopsies
as described in Materials and methods. Cells were cultivated for five days and the production of proteins was measured in conditioned culture
supernatants by ELISA. Productions were normalized to DNA content. Results are expressed as the percent of the production of N/R SC. Results
are expressed as mean ± SEM of 10 independent experiments performed with synovial cells isolated from 10 different donors. Comparison of
mean values was performed by Mann-Whitney non-parametric analysis. *** P < 0.001: production of I SC cells was significantly different than
production of N/R SC.
Figure 6 Effect of IL-1b on pro (A) and anti-angiogenic (B) factor gene expression. FSC were cultured for 5 or 24 h in the absence or in
the presence of IL-1b (1 ng/ml). Total RNA was isolated in cellular extract and pro-angiogenic (VEGF, bFGF, NGF, Ang-1 and MMP-2) (A) and
anti-angiogenic (TSP-1, TSP-2 and VEGI) (B) mRNA expression was analysed by real time RT PCR. Results are expressed as a percentage of the
basal condition (cells incubated without IL-1b). Each condition was tested in duplicate. Results are expressed as mean ± SEM of three
independent experiments.
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and NGF were rapidly enhanced after 5 h of treatment,
while Ang-1 increased after 24 h suggesting a delayed
involvement of Ang-1 in angiogenesis. Our findings are
in complete agreement with previous studies demon-
strating the up-regulation of VEGF and NGF gene
expression in SFC by IL-1b [33,34]. Using Northern blot
analysis, Gravalesse et al. [35] reported that TNF-a but
not IL-1b stimulated mRNA of Ang-1 in RA SFC. This
discrepancy can be explained by the differences in the
origin of the cells and by the method used to study
gene expression. More surprising was the time-depen-
dent regulation of anti-angiogenic VEGI and TSP-1
gene expression. A stimulating effect of IL-1b was
observed after 5 h but an inhibitory effect after 24 h.
This complex regulation suggests a cascade of indirect
and time dependent events which negatively regulate
VEGI and TSP-1 production. A transitory IL-1b-depen-
dent molecule expression could be responsible for the
Figure 7 Effect of CS on IL-1b-dependent anti-angiogenic gene expression. SFC were pre-incubated with CS (10, 50, 200 μg/ml) for 1 h. IL-
1b (1 ng/ml) was added to culture medium for 5 or 24 h incubation. Total RNA was isolated in SFC and VEGI (A), TSP-1 (B) and TSP-2 (C) mRNA
expression was analyzed by real time RT PCR. Results are expressed as a percentage of the control (cells incubated without CS). Each condition
was tested in duplicate. Results are expressed as mean ± SD of five independent experiments. Comparison of mean values was performed by
Mann-Whitney non-parametric analysis. ***P < 0.001: CS treated group was significantly different from control.
Figure 8 Effect of CS on IL-1b-dependent VEGI and TSP-1 production. SFC were pre-incubated with CS (10, 50, 200 μg/ml) for 1 h. IL-1b (1
ng/ml) was added to culture medium for 24 h. TSP-1 and VEGI were measured in conditioned culture supernatants by ELISA. Results are
normalized to DNA content. Results are expressed as a percentage of the control (cells incubated without CS). Each condition was tested in
triplicate. Results are expressed as mean ± SD of three independent experiments. Comparison of mean values was performed by Mann-Whitney
non-parametric analysis. ***P < 0.001: CS treated group was significantly different from control.
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early stimulation of VEGI and TSP-1. The disappearance
of this molecule with time could explain the loss of the
stimulating effect observed after 5 h. In addition, the
inhibitory effect could be linked to the presence of a
late IL-1b-dependent molecule expression. Little infor-
mation is accessible on the regulation of VEGI, TSP-1
and -2 by IL-1b. The down-regulation of TSP-1 was
reported in human endothelial cells and rabbit chondro-
cytes [36,37] but never in SFC. Interestingly, a time
dependent phorbol-myristate-acetate (PMA) regulation
of VEGI expression (stimulation for 6 h, inhibition for
24 h) was described in endothelial cells [38]. This obser-
vation supports our result showing a biphasic effect of
IL-1b on VEGI gene expression.
Our data suggest that after 24 h of treatment, IL-1b
induced an imbalance between pro- and anti-angiogenic
factors production in SFC in favor of pro-angiogenic
status and by this way could promote synovial mem-
brane angiogenesis.
Finally, in the present study we examined the effect of
CS on the expression of pro- and anti-angiogenic factors
in OA SFC. Although CS is currently used in the man-
agement in OA, its mechanism of action has not been
yet fully clarified. Anti-inflammatory properties of CS
were largely described but less is known about its effect
on angiogenesis [39]. Macrophage migration on
endothelium is one of the key steps for angiogenesis
[40]. Macrophages promote angiogenesis by the synth-
esis of angiogenic factors including VEGF and by the
remodeling of the extracellular matrix. An in vitro study
has demonstrated that CS acted as an inhibitor of
monocytes THP-1 cell migration suggesting that CS
could prevent angiogenesis [41]. Our results reveal that
CS counteracts the IL-1b-dependent TSP-1 and VEGI
down-regulation at both gene and protein levels. This
finding could suggest an anti-angiogenic effect of CS.
Conclusions
For the first time, we demonstrated the presence of pro-
inflammatory and pro-angiogenic pathways in the I
areas of synovial membrane compared to N/R. IL-1b
induced an imbalance between pro- and anti-angiogenic
factors in SFC and CS tended to normalize this IL-1b-
induced imbalance. Since angiogenesis is a key process
in OA progression, our data suggest that the beneficial
role of CS in OA management could, at least in part,
derive from its anti-angiogenic properties.
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